Cytokinetics Incorporated Price to Earnings Ratio (PE) Ratios, (CYTK) Valuation Ranking and Trends, Fundamental Ratios

CYTK Price to Earnings Ratio	(Sep 30 2025)	(Jun 30 2025)	(Mar 31 2025)	(Dec 31 2024)	(Sep 30 2024)
Diluted EPS 12 Trailing Months	III. Quarter	II. Quarter	I. Quarter	IV. Quarter	III. Quarter
PE (TTM) Ratio	current -	-	-	-	-
Diluted EPS TTM Y / Y Change	13.87 %	-8.2 %	-5.17 %	-6.6 %	0.26 %
Diluted EPS Y / Y Change	87.5 %	-14.5 %	2.26 %	-21.28 %	0.74 %
Stock performance	to date 63.61 %	-12.3 %	-11.61 %	-4.55 %	-11.93 %

Price to earnings ratio Comment

Cytokinetics Incorporated's recorded net loss in trailing twelve months.

Within Healthcare sector Cytokinetics Incorporated has the lowest Price to earnings ratio.

What is Price to Earnings Ratio?
What is Cytokinetics Incorporated Market Share?

Price to earnings ratio Company Ranking
Within:	No.
Industry	#0
Sector	#0
S&P 500	#2

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.